Glaxo agrees to pay $956.8 million criminal fine

Pharmaceutical giant to plead guilty and pay penalty for marketing drugs for unapproved uses

It’s probably not the way GlaxoSmithKline (GSK) had hoped to start the second half of the year. The U.S. unit of GSK today agreed to plead guilty and pay a criminal fine of $956.8 million for marketing drugs for unapproved uses.

The London-based pharmaceutical giant admits in a charging document that it didn’t report safety data of its Avandia diabetes drug to regulators, unlawfully marketed Wellbutrin for weight loss and other purposes for which it wasn’t approved by U.S. regulators and illegally promoted Paxil for adolescents and children.

Join the Conversation

Advertisement. Closing in 15 seconds.